



Scientific Committee on Consumer Safety

SCCS

**OPINION ON**  
**2-Nitro-5-glyceryl methylaniline**

**COLIPA n° B60**

The SCCS adopted this opinion at its 16<sup>th</sup> plenary meeting  
of 18 September 2012

### About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

They are: the Scientific Committee on Consumer Safety (SCCS), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

### SCCS

The Committee shall provide opinions on questions concerning all types of health and safety risks (notably chemical, biological, mechanical and other physical risks) of non-food consumer products (for example: cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products such as detergents, etc.) and services (for example: tattooing, artificial sun tanning, etc.).

### Scientific Committee members

Jürgen Angerer, Ulrike Bernauer, Claire Chambers, Qasim Chaudhry, Gisela Degen, Elsa Nielsen, Thomas Platzek, Suresh Chandra Rastogi, Vera Rogiers, Christophe Rousselle, Tore Sanner, Jan van Benthem, Jacqueline van Engelen, Maria Pilar Vinardell, Rosemary Waring, Ian R. White

### Contact

European Commission  
Health & Consumers  
Directorate D: Health Systems and Products  
Unit D3 - Risk Assessment  
Office: B232 B-1049 Brussels  
[Sanco-SCCS-Secretariat@ec.europa.eu](mailto:Sanco-SCCS-Secretariat@ec.europa.eu)

© European Union, 2012

ISSN 1831-4767

ISBN 978-92-79-30774-4

Doi:10.2772/87755

ND-AQ-12-024-EN-N

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

[http://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/index\\_en.htm](http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm)

**ACKNOWLEDGMENTS**

## WG members

Prof. J. Angerer  
Dr. C. Chambers  
Dr. E. Nielsen  
Dr. W. Lilienblum (associated scientific advisor)  
Prof. T. Platzek (chairman)  
Dr. S.C. Rastogi  
Dr. C. Rousselle  
Prof. T. Sanner  
Dr. J. van Benthem  
Prof. M.P. Vinardell (rapporteur)  
Dr. I.R. White

## External experts

Dr. Mona-Lise Binderup National Food Institute, Denmark

Keywords: SCCS, scientific opinion, 2-Nitro-5-glyceryl methylaniline, B60, directive 76/768/ECC, CAS 80062-31-3, EC 279-383-3

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on 2-Nitro-5-glyceryl methylaniline, 18 September 2012

---

**TABLE OF CONTENTS**

3.1	Chemical and Physical Specifications.....	6
3.1.1	Chemical identity .....	6
3.1.2	Physical form .....	6
3.1.3	Molecular weight .....	6
3.1.4	Purity, composition and substance codes.....	6
3.1.5	Impurities / accompanying contaminants .....	7
3.1.6	Solubility .....	7
3.1.7	Partition coefficient (Log Pow) .....	7
3.1.8	Additional physical and chemical specifications.....	8
3.1.9	Homogeneity and Stability .....	8
3.2	Function and uses .....	8
3.3	Toxicological Evaluation .....	9
3.3.1	Acute toxicity .....	9
3.3.2	Irritation and corrosivity .....	9
3.3.3	Skin sensitisation.....	11
3.3.4	Dermal / percutaneous absorption.....	12
3.3.5	Repeated dose toxicity .....	15
3.3.6	Mutagenicity / Genotoxicity .....	17
3.3.7	Carcinogenicity.....	27
3.3.8	Reproductive toxicity.....	27
3.3.9	Toxicokinetics .....	29
3.3.10	Photo-induced toxicity .....	29
3.3.11	Human data.....	29
3.3.12	Special investigations .....	29
3.3.13	Safety evaluation (including calculation of the MoS).....	29
3.3.14	Discussion .....	29

## 1. BACKGROUND

Submission I, II and III for 2-Nitro-5-glyceryl methylaniline CAS n. 80062-31-3 (COLIPA number B060) were submitted by COLIPA in July 1993, in November 2001 and in July 2005 respectively.

The Scientific Committee on Cosmetic Products expressed its last opinion (SCCP/1162/08) with the following conclusions:

*The SCCP is of the opinion that the safety of 2-nitro-5-glyceryl methylaniline cannot be assessed based on the data submitted. Before any further consideration, an appropriate in vivo test to study the induction of gene mutations has to be submitted. 2-Nitro-5-glyceryl methylaniline is a secondary amine, and thus, prone to nitrosation. It should not be used in combination with nitrosating agents. The nitrosamine content should be < 50 ppb.*

Submission IV was submitted on 9 October 2009 by Colipa containing the results of an *in vivo* Unscheduled DNA Synthesis (UDS) assay and data to demonstrate the safety of the ingredient in oxidative colouring products.

In 2011 the Scientific Committee on Consumer Safety (SCCS) issued the general request to receive stability data for non-oxidative hair dyeing ingredients when used under oxidative conditions. The applicant wants to support the use of this hair dye under these conditions and therefore sent a supplement to submission IV on B060.

## 2. TERMS OF REFERENCE

1. Does the SCCS consider 2-Nitro-5-glyceryl methylaniline, Hair Dye B060, safe for use as an oxidative and non-oxidative hair dye with a concentration on-head of maximum 0.8% and 1.0 % respectively taken into account the scientific data provided?
2. And/or does the SCCS recommend any further restrictions with regard to the use of 2-Nitro-5-glyceryl methylaniline, Hair Dye B060, in any hair dye formulations?

## 3. OPINION

### 3.1 Chemical and Physical Specifications

#### 3.1.1 Chemical identity

##### 3.1.1.1 Primary name and/or INCI name

2-Nitro-5-glyceryl methylaniline (INCI name)

##### 3.1.1.2 Chemical names

1-Methylamino-2-nitro-5-(2,3-dihydroxy-propyloxy)-benzene  
3-[3-(methylamino)-4-nitrophenoxy]-propane-1,2-diol


##### 3.1.1.3 Trade names and abbreviations

Imexine FT

**3.1.1.4 CAS / EC number**

CAS: 80062-31-3

EC: 279-383-3

**3.1.1.5 Structural formula****3.1.1.6 Empirical formula**Formula: C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>5</sub>**3.1.2 Physical form**

Yellow powder with green highlights

**3.1.3 Molecular weight**

Molecular weight: 242 g/mol

**3.1.4 Purity, composition and substance codes**

The analytical study of 2-Nitro-5-glyceryl methylaniline was carried out on five batches:

- Batch Op. 8 refers to an analytical certificate (April 1990)
- Batch Op. T107 refers to analytical certificate (October 1993)
- Batch Op. 77 refers to an analytical certificate (September 1994)
- Batch 0504494 refers to an analytical certificate (January 2001)
- Batch 0122117, results of an analytical study provided (no date)

Description/Batch No.	OP.8	Op.77	Op.T107	0504494	0122117
Identification		NMR, IR, MS, Vis-spectrometry			NMR, IR, MS, Vis-spectrometry, Elemental analysis
Content					
UV-Vis spectrometry, content at 413 nm (w/w)	> 99	98	98.3	98	98.4
HPLC (% peak area)	> 99.5	> 99.5			> 99.5
Water content, %(w/w)		0.34	0.06		0.1
Ash content, %(w/w)					< 0.1
Impurities, % (w/w)					
A*				< 0.020	< 0.010 ND
B*				< 0.020	< 0.010 ND
C		0.0075	0.004		< 0.010 ND
D		0.095	0.12	< 0.25	< 0.010 D
E				< 0.4	< 0.010 D
F*		< 0.01			
G*		< 0.01			
Residual solvent ppm					
Isopropanol		100			

## Opinion on 2-nitro-5-glyceryl methylaniline

Methanol		< 50			
Toluene		330			
Solketal**					500

ND: Not detected

D: Detected

\* The synthetic pathway leading to batches 0504494 and 0122117 was different from the synthetic pathway leading to batches Op. 8, Op. T107 and Op. 77. Hence, impurities A and B were checked only in batches 0504494 and 0122117 and impurities F and G in batch Op. 77, respectively.

Possible impurities which may originate from reagents and intermediate reaction products were checked:

A: 2,4-difluoro-1-nitrobenzene

B: 5-fluoro-2-nitrophenyl)-methylamine

C: 3-methylamino-4-nitrophenol or (5-hydroxy-2-nitrophenyl) methylamine

D: 1-(3-methylamino-4-nitrophenyl)-2,3-isopropylidenglycerol or 5-[2,2-dimethyl-(1,3)dioxolan-4-ylmethoxy]-2-nitrophenylmethylamine

E: 2,4-dimethylaminonitrobenzene

F: 2,4-dichloro-1-nitrobenzene

G: 5-chloro-2-nitrophenyl)-methylamine

\*\* Solketal: (2,2-dimethyl-1,3-dioxolan-4-yl)methanol

### 3.1.5 Impurities / accompanying contaminants

See 3.1.4

Heavy Metals in batch n° 0122117:

- As, Sb, Hg: each < 5 mg/k

- Cd: < 10 mg/kg

- Pb: < 20 mg/kg

Ash content: < 0.1 g/100g

### 3.1.6 Solubility

Water: 1.43 g/l at 20°C EEC method A6

Ethanol: < 1 g/100ml at 22°C after 24 h

DMSO: > 20 g/100 ml at 22°C after 24 h

### 3.1.7 Partition coefficient (Log Pow)

Log P<sub>ow</sub>: 1.14 at 25°C and pH 6.19 EEC method A8

### 3.1.8 Additional physical and chemical specifications

Melting point: 95-97 °C (thermo-microscopic method)

105 °C (differential calorimetry)

Boiling point: /

Flash point: /

Vapour pressure: /

Density: /

Viscosity: /

pKa: /

Refractive index: /

pH: /

UV\_Vis spectrum (200-800 nm): absorbance at 233.9 (λ<sub>max</sub>), 253.9, 312.2 and 412.6 nm

### 3.1.9 Homogeneity and Stability

The homogeneity testing of 2-Nitro-5-glyceryl methylaniline (batch 0122117) was performed at 1 and 100 mg/mL in 0.5% aqueous methylcellulose (MC) on the day of preparation. The stability testing of 2-Nitro-5-glyceryl methylaniline (batch 0122117) in

dosage forms was performed at 1 and 100 mg/mL in 0.5% MC, at 0.1 and 250 mg/mL in DMSO and at 1 and 250 mg/mL in DMF over a 4-hour period at room temperature, protected from light and under inert gas atmosphere. The deviation from nominal concentrations in all cases was maximum 9%.

A typical oxidative hair dye formulation containing 1.6% 2-Nitro-5-glyceryl methylaniline was mixed 1:1 with hydrogen peroxide containing developer. The content of 2-Nitro-5-glyceryl methylaniline in the mixture was shown to be stable for 30 min study period, maximum deviation from original concentration 1.5%.

### General Comments on physico-chemical characterisation

- 2-Nitro-5-glyceryl methylaniline is a secondary amine, and thus, it is prone to nitrosation. Nitrosamine content in the test material is not reported.
- The stability of 2-Nitro-5-glyceryl methylaniline in typical hair dye formulations is not reported

## 3.2 Function and uses

2-Nitro-5-glyceryl methylaniline is used in semi permanent hair colouring products at a maximum concentration of 1%. The formulation is applied as such without any further dilution. 2-Nitro-5-glyceryl methylaniline is used in oxidative hair dye formulation at on head concentration of up to 0.8%.

## 3.3 Toxicological Evaluation

### 3.3.1 Acute toxicity

#### 3.3.1.1 Acute oral toxicity

Guideline:	OECD 401
Species/strain:	Sprague – Dawley, fasted
Group size:	10 per sex
Test substance:	IMEXINE FT
Batch:	Op. 8
Purity:	99.9%
Dose:	1000 mg/kg bw and 2000 mg/kg bw
Route:	Oral
Exposure:	single administration and 14-days observation
GLP:	in compliance
Study period:	April 1992

Ten Sprague-Dawley rats per sex were exposed to 2-nitro-5-glyceryl methylaniline (B060) at the dose of 1000 mg/kg bw and 2000 mg/kg bw in 1% aqueous methylcellulose. Animals were observed twice daily for mortality/morbidity and daily for clinical signs over a period of 14 days. Body weights were recorded on day 1 prior to treatment, and on days 5, 8 and 15 thereafter. All study animals were subjected to a macroscopic examination.

Results



At 2000 mg/kg bw, 4/5 males and 5/5 females died 24 to 48 hours after treatment. Sedation and dyspnoea were observed 15 minutes after exposure at both dose levels. Ptosis was also observed in a few animals exposed to 2000 mg/kg bw. No mortality was observed at 1000 mg/kg bw/day, where clinical signs included sedation, dyspnoea, lateral recumbency and orange colouration of extremities (reversible from day 3 onwards). No effect on body weight gain was observed at either dose level. At necropsy, black areas were noted on the stomach in three animals treated at 2000 mg/kg bw; orange discolouration of all tissues and organs was observed in animals found dead.

#### Conclusion

The maximal non-lethal dose of B060 was higher than 1000 mg/kg bw and lower than 2000 mg/kg bw after a single oral administration in fasted rats.

Ref.: 1

#### 3.3.1.2 Acute dermal toxicity

No data submitted

#### 3.3.1.3 Acute inhalation toxicity

No data submitted

### 3.3.2 Irritation and corrosivity

#### 3.3.2.1 Skin irritation

##### ***Taken from SCCNFP/0688/03***

Guideline:	OECD n° 404
Species:	rabbit (New Zealand white)
Group size:	3 males
Substance:	IMEXINE FT at 1% in 1,2-propanediol
Batch:	op 8
Purity:	99.9%
Dose:	0.5 ml of a 1% suspension
GLP:	in compliance
Study period:	March 1992

0.5 ml of a 1% suspension of the test substance in 1,2-propanediol was applied to the right clipped dorsal flank of 3 male rabbits. The left flank did not receive any substance and served as a control. The test substance was kept in contact with the skin for 4 hours under a semi-occlusive patch. Any reactions were evaluated 60 minutes and 24, 48 and 72 hours following the removal of the semi-occlusive dressing. At termination, histopathological examination of the treated skin was carried out.

#### Results

No oedema was noted in any of the 3 animals. Reddish coloration of the skin made it impossible to evaluate erythema. Histological examination of samples of treated skin revealed no relevant abnormalities.

#### Conclusion

The test substance was considered as non-irritant to rabbit skin when applied as a 1% suspension in 1,2-propanediol.

Ref.: 2

### 3.3.2.2 Mucous membrane irritation

#### **Taken from SCCNFP/0688/03**

Guideline: OECD n° 405  
 Species: rabbit (New Zealand white)  
 Route: eye  
 Group size: 3 males  
 Substance: IMEXINE FT, 1% suspended in 1,2-propanediol  
 Batch: op 8  
 Purity: 99.9%  
 Dose: 0.1 ml of a 1% suspension  
 GLP: in compliance  
 Study period: March 1992

0.1 ml of a 1% suspension of the test substance in 1,2-propanediol was instilled into the left eye of 3 male rabbits, the right eyes served as control. The material was not rinsed out. Eye irritation was scored one hour, 24, 48 and 72 hours following instillation.

#### Results

One hour after instillation, slight chemosis and redness of the conjunctivae were observed. After 24, 48 and 72 hours, no reactions to the conjunctivae were seen. No irritation of the iris and no corneal opacity were noted.

#### Conclusion

The test substance was considered as non-irritant to the rabbit eye when applied as a 1% suspension in 1,2-propanediol.

Ref.: 3

#### Comment

The SCCS concluded that a 1% suspension caused some slight and transient irritation of the rabbit eye.

### 3.3.3 Skin sensitisation

#### **Local Lymph Node Assay (LLNA)**

Guideline: OECD 429 (2002)  
 Species: CBA/J mouse, nulliparous and non-pregnant females  
 Group: 28 females (5 test groups, 1 positive control group, 1 vehicle control group)  
 Substance: 2-nitro-5-glyceryl methylaniline  
 Batch: 0122117  
 Purity: 98.4%  
 Concentrations: 0.5, 1, 2.5, 5 and 10% in dimethylformamide (DMF)  
 Dose: 25 µl  
 Vehicle: dimethylformamide (DMF)  
 Control: α-hexylcinnamaldehyde (HCA), 25% in DMF  
 GLP: in compliance  
 Study period: 24 August – 6 September 2004

Twenty-eight female CBA/J mice were allocated to seven groups:

- five treated groups of four animals receiving the test item 2-nitro-5-glyceryl methylaniline (B060) at the concentration of 0.5, 1, 2.5, 5 or 10%,
- one negative control group of four animals receiving the vehicle (DMF),
- one positive control group of four animals receiving the reference item, HCA, a

moderate sensitizer, at the concentration of 25% in DMF.

During the induction phase, the test item, vehicle or reference item was applied over the ears (25 µL per ear) for 3 consecutive days (days 1, 2 and 3).

On day 6, the mice received an intravenous injection of 250 µl of 0.9% NaCl containing 20 µCi of tritiated methyl thymidine. Approximately five hours later, the mice were sacrificed by cervical dislocation and the auricular lymph nodes were excised. The lymph nodes were pooled for each experimental group. The proliferation of lymphocytes was measured by incorporation of tritiated methyl thymidine. The obtained values were used to calculate stimulation indices (SI).

## Results

Systemic clinical signs and mortality: no clinical signs and no mortality related to treatment with the test item were noted.

Proliferation assay: the stimulation index (SI) was below 3 in all test groups (see table). The positive control (HCA at 25% in DMF) caused a SI of 7.47. No EC3 value was calculated, since all stimulation indices were below 3.

The results are presented in the following table:

Concentration (%)	Stimulation index
0.5	1.67
1.0	1.80
2.5	2.04
5.0	1.38
10.0	0.98
25% α-hexylcinnamaldehyde	7.47

## Conclusion

Under the conditions of this Local Lymph Node Assay, 2-nitro-5-glyceryl methylaniline did not induce skin sensitisation.

Ref.: 4

## Comment

The highest concentration of the test substance (10%) tested is considered too low. 25% was not tested, justified by the authors by reference to skin irritancy (moderate increase in ear thickness) in the preliminary test to that concentration. The rationale is not according to the test guideline which states that exposure shall be maximized whilst avoiding systemic toxicity and excessive local skin irritation.

No conclusion regarding the sensitising potential of 2-nitro-5-glyceryl methylaniline can be drawn.

### 3.3.4 Dermal / percutaneous absorption

#### Submission IV, 2009

Guideline:	OECD 428 (2004)
Tissue:	Human skin (abdomen and/or breast) from four donors
Membranes:	dermatomed, thickness of ca 400 µm
Skin integrity:	permeability coefficient (Kp) for tritiated water
Method:	9 mm flow-through automated diffusion cells
Replicate cells:	11 chambers
Test substance:	2-nitro-5-glyceryl-methylaniline [ <sup>14</sup> C]-2-nitro-5-glyceryl-methylaniline (8.38 MBq/mg)
Batch:	0137906 2928JRD001-1 (radio-labelled)

## Opinion on 2-nitro-5-glyceryl methylaniline

Purity:	99.9% (HPLC) 98.8% (HPLC) (radio-chemical purity)
Receptor fluid:	saline (0.9% sodium chloride (w/v) containing 0.01% sodium azide), supplemented with 5% Bovine Serum Albumine (BSA, w/v)
Test formulation:	Liquid Hair Color Yellow - Formula 32745 RDK, containing 1.6% (w/w) test substance
Placebo formulation:	Liquid Hair Color Blank - Formula 33198 RDK
Developer:	Liquid Hair Color Developer - Formula 22724 RK1
Dose applied:	20 mg/cm <sup>2</sup>
Solubility receptor fluid:	650 µg/mL
Analytical method:	liquid scintillation counter
GLP:	in compliance
Study period:	22 September – 7 October 2008

The *in vitro* percutaneous absorption of 2-nitro-5-glyceryl-methylaniline under oxidative conditions was determined in human dermatomed skin mounted on flow-through diffusion cells. 2-nitro-5-glyceryl-methylaniline was incorporated into a typical oxidative hair dye formulation at 1.6% (w/w) before mixing with peroxide developer (1:1, w/w) to yield a final concentration of 0.8% (w/w).

The integrity of the skin membranes was established by determination of the permeation coefficient for tritiated water, which was  $< 2.5 \times 10^{-3}$  cm/h for all selected skin membranes.

20 mg/cm<sup>2</sup> of the test preparation were applied on the surface of 12 skin samples obtained from 4 different donors. After 30 minutes of exposure, the skin surface was rinsed to remove the hair dye remaining on the skin surface. Twenty four hours after application, the percutaneous absorption of 2-nitro-5-glyceryl-methylaniline was determined by measuring its concentration by liquid scintillation counting.

Table 1: Summary results

concentrate	% of applied dose	µg <sub>eq</sub> ·cm <sup>-2</sup>
Skin wash	94.5 ± 1.7	158.8 ± 29.2
Dislodgeable dose <sup>*</sup>	94.6 ± 1.6	159.0 ± 29.2
Stratum corneum	0.57 ± 0.30	0.95 ± 0.50
Skin (epidermis + dermis)	0.66 ± 0.59	1.07 ± 0.89
Receptor fluid	0.82 ± 0.65	1.29 ± 0.92
Unabsorbed dose <sup>**</sup>	95.2 ± 1.4	160.0 ± 29.2
Absorbed dose <sup>***</sup>	1.49 ± 1.20	2.39 ± 1.72
Total recovery	96.7 ± 1.3	162.4 ± 28.8

<sup>\*</sup> Dislodgeable dose is defined as the amount of test substance removable from the application site (skin wash, cotton swabs and donor compartment wash)

<sup>\*\*</sup> Unabsorbed dose is defined as the dislodgeable dose including the amount recovered in the stratum corneum

<sup>\*\*\*</sup> Absorbed dose (dermal delivery) is defined as the amount in the receptor fluid, the receptor compartment wash and skin membrane, excluding tape strips

The amounts of 2-nitro-5-glyceryl-methy considered to be systemically available after dermal application of a typical oxidative hair colouring mixture containing this hair dye

ingredient at the final (on-head) concentration of 0.8% were estimated to be  $2.39 \pm 1.72 \mu\text{g}/\text{cm}^2$  (1.49 % of the applied dose) under use conditions.

Ref.: 4 (subm IV)

#### Comment

Under the experimental conditions, the dermal absorption was mean + SD ( $2.39 + 1.72 = 4.11 \mu\text{g}/\text{cm}^2$ ), which can be used for the calculation of the MoS.

### Submission III, 2005

Guideline:	OECD draft 428 (2000)
Tissue:	dermatomed human (female) abdominal skin, 400 $\mu\text{m}$ thickness
Group size:	8 skin preparations from 4 different donors
Diffusion cells:	9 mm flow-through diffusion cell, 0.64 $\text{cm}^2$ area
Skin integrity:	permeation coefficient for tritiated water ( $< 2.5 \times 10^{-3} \text{ cm}/\text{hour}$ )
Test substance:	2-nitro-5-glyceryl-methylaniline [ $^{14}\text{C}$ ]- 2-nitro-5-glyceryl-methylaniline, 8.46 MBq/mg, 2064.4 MBq/mmol
Batch:	0122117 SEL/1439 (radio-labelled)
Purity:	98.4% 98.4% (HPLC) (radio-labelled)
Test item:	formulation 1036515, 0.9% (w/w) test substance
Doses:	20 $\text{mg}/\text{cm}^2$
Receptor fluid:	phosphate-buffered saline containing 0.01% sodium azide (w/v) and 5% bovine serum albumin
Solubility receptor fluid:	650 $\mu\text{g}/\text{ml}$
Stability:	considered sufficient during 'life phase' of study
Method of Analysis:	liquid scintillation counting
GLP:	in compliance
Study period:	24 – 31 January 2005

The *in vitro* percutaneous absorption of 2-nitro-5-glyceryl-methylaniline in a semi-permanent hair dye formulation was determined in human dermatomed skin mounted in flow-through diffusion cells.

The integrity of 20 skin samples was established by determination of the permeation coefficient for tritiated water. From these, 8 skin samples (2 from each of the 4 donors) with a permeation coefficient of  $< 2.5 \times 10^{-3} \text{ cm}\cdot\text{h}^{-1}$  were selected for the study.

20  $\text{mg}/\text{cm}^2$  of a formulation containing 0.9% 2-nitro-5-glyceryl-methylaniline was applied on the skin surface. After the 30-minute exposure period, the test substance was removed from the application site by washing and using cotton swabs. Twenty-four hours after application, each skin was tape stripped 10 times per skin membrane. The cutaneous distribution of 2-nitro-5-glyceryl-methylaniline was assessed by Liquid Scintillation Counting in the skin wash, stratum corneum (isolated by tape stripping), skin samples and receptor fluid.

#### Results

Most of the 2-nitro-5-glyceryl-methylaniline was recovered in the skin wash after 30 min of exposure. After 24 hours, 0.20% of the applied dose was retained in the stratum corneum; those amounts are not considered to be percutaneously absorbed. At the end of the experiment, 0.11% of the dose applied was found in the skin (epidermis + dermis).

The mean penetration of 2-nitro-5-glyceryl-methylaniline into the receptor fluid after 24 hours was  $0.27 \mu\text{eq}/\text{cm}^2$ , representing 0.13% of the dose applied. The mean maximal flux

## Opinion on 2-nitro-5-glyceryl methylaniline

for the absorption of 2-nitro-5-glyceryl-methylaniline through human skin was 0.0183  $\mu\text{geq}/\text{cm}^2$  per hour. No clear difference in penetration of 2-nitro-5-glyceryl-methylaniline was observed between the four donors.

The mean total absorption (dermal delivery), defined as the compound-related radioactivity present in the receptor fluid, the receptor compartment wash and the skin (excluding tape strips), was 0.51  $\mu\text{geq}/\text{cm}^2$ , corresponding to 0.24% of the dose applied.

The results obtained are summarised in the table below:

Cell number	Amount recovered ( $\mu\text{geq}/\text{cm}^2$ )								mean	SD
	R1	R2	R3	R4	R5	R6	R7	R8		
<b>Donor</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>1</b>	<b>3</b>	<b>4</b>	<b>2</b>		
<b>Skin wash</b>	195.3	192.9	221.0	192.3	204.0	199.2	218.2	204.3	<b>203.4</b>	<b>11.0</b>
<b>Cotton swabs</b>	0.04	0.09	0.06	0.07	0.05	0.05	0.04	0.05	<b>0.06</b>	<b>0.02</b>
<b>Donor compartment</b>	0.00	0.01	0.00	0.01	0.01	0.00	0.01	0.01	<b>0.01</b>	<b>0.00</b>
<b>Dislodgeable dose (1)</b>	195.4	193.0	221.1	192.4	204.1	199.2	218.2	204.3	<b>203.5</b>	<b>11.0</b>
<b>Tape strips</b>	0.28	0.56	0.54	0.42	0.31	0.50	0.36	0.42	<b>0.42</b>	<b>0.10</b>
<b>Unabsorbed dose (2)</b>	195.6	193.6	221.6	192.8	204.4	199.7	218.6	204.7	<b>203.9</b>	<b>11.0</b>
<b>Receptor fluid and wash</b>	0.05	0.11	0.47	0.32	0.19	0.67	0.30	0.04	<b>0.27</b>	<b>0.22</b>
<b>Skin</b>	0.13	0.34	0.30	0.27	0.19	0.28	0.17	0.22	<b>0.24</b>	<b>0.07</b>
<b>Total absorption</b>	<b>0.18</b>	<b>0.45</b>	<b>0.77</b>	<b>0.60</b>	<b>0.38</b>	<b>0.94</b>	<b>0.46</b>	<b>0.27</b>	<b>0.51</b>	<b>0.25</b>
<b>Total recovery</b>	195.8	194.0	222.4	193.4	204.8	200.7	219.0	205.0	<b>204.4</b>	<b>11.1</b>

Cell number	Amount recovered (%)								mean	SD
	R1	R2	R3	R4	R5	R6	R7	R8		
<b>Donor</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>1</b>	<b>3</b>	<b>4</b>	<b>2</b>		
<b>Skin wash</b>	92.8	92.4	107.5	91.4	97.2	94.8	105.1	97.2	<b>97.3</b>	<b>6.0</b>
<b>Cotton swabs</b>	0.021	0.044	0.030	0.032	0.025	.026	0.018	0.023	<b>0.027</b>	<b>0.008</b>
<b>Donor compartment</b>	0.002	0.005	0.001	0.005	0.006	0.001	0.003	0.004	<b>0.003</b>	<b>0.002</b>
<b>Dislodgeable dose (1)</b>	92.8	92.4	107.5	91.5	97.2	94.9	105.1	97.2	<b>97.3</b>	<b>6.0</b>
<b>Tape strips</b>	0.13	0.27	0.26	0.20	0.15	0.24	0.17	0.20	<b>0.20</b>	<b>0.05</b>
<b>Unabsorbed dose (2)</b>	93.0	92.7	107.8	91.7	97.4	95.1	105.2	97.4	<b>97.5</b>	<b>6.0</b>
<b>Receptor fluid and wash</b>	0.02	0.05	0.23	0.15	0.09	0.32	0.14	0.02	<b>0.13</b>	<b>0.10</b>
<b>Skin</b>	0.06	0.16	0.15	0.13	0.09	0.13	0.08	0.11	<b>0.11</b>	<b>0.03</b>
<b>Total absorption</b>	<b>0.09</b>	<b>0.22</b>	<b>0.37</b>	<b>0.28</b>	<b>0.18</b>	<b>0.45</b>	<b>0.22</b>	<b>0.13</b>	<b>0.24</b>	<b>0.12</b>
<b>Total recovery</b>	93.0	92.9	108.2	92.0	97.6	95.5	105.5	97.5	<b>97.8</b>	<b>6.0</b>

- (1) Amount in skin wash, cotton swabs, and donor compartment wash
- (2) Amount in dislodgeable dose and tape strips
- (3) Amount in receptor fluid, receptor compartment wash and the skin (excluding tape strips)

#### Conclusion

Under the experimental conditions, the study authors concluded that the mean total absorption (= amount present in the receptor fluid, receptor compartment wash and the skin, excluding tape strips) was 0.51  $\mu\text{geq}/\text{cm}^2$  (0.24% of the applied dose) under non-oxidative conditions.

Ref.: 13

#### Comment

Too few chambers were used. The mean + 2 standard deviations ( $1.01 \mu\text{g}/\text{cm}^2$  ( $0.51 + 2 \times 0.25$ )), corrected for the use of a lower concentration (0.9 instead of 1.0%)  $1.01 \times 10/9 = 1.12 \mu\text{g}/\text{cm}^2$  should be used for the calculation of the Margin of Safety under non-oxidative conditions.

It should be noted that the dermal absorption under non-oxidative conditions was significantly lower than under oxidative conditions, which is unusual.

### 3.3.5 Repeated dose toxicity

#### 3.3.5.1 Repeated Dose (30 days) oral toxicity

##### ***Taken from opinion SCCNFP/0688/03***

Guideline:	OECD n° 407
Species:	Sprague Dawley rat - CrI CD (SD) BR
Group size:	10 males and 10 females
Substance:	B60 suspended in 0.5% carboxymethylcellulose
Batch:	op 6
Purity:	99.9%
Dose levels:	0, 100, 300 and 1000 mg/kg bw/day in a volume of 5 ml/kg bw
Exposure:	29 or 30 days
GLP:	in compliance
Study period:	14 February 1990 – 16 March 1990

The test substance, suspended in 0.5% carboxymethylcellulose, was administered at 100, 300 and 1000 mg/kg bw/day daily for 29 or 30 days by gavage. The control group received the vehicle alone.

All animals were observed twice daily for mortality and once daily for clinical signs. Body weight and food consumption were recorded at weekly intervals. Ophthalmoscopic examinations were performed before the start of treatment and during week 4. Blood samples were taken from all animals during week 4 for haematological and clinical chemistry investigations. Urine samples were collected during week 4 from all animals. At autopsy, organ weights were recorded and the main organs were examined macroscopically and histologically. The eye was not examined histologically.

##### Results

No mortalities occurred due to the test substance. One mortality in the male high dose group was considered to be due to a gavage error. Body weights and food consumption of treated animals were comparable to controls. Hypersalivation was noted in 2/10 males and 5/10 females in the group given 1000 mg/kg bw/day. Due to the nature of the compound, the urine of the treated groups was coloured yellow throughout the test period and a yellowish staining of the fur was noted in rats given B60 at 300 or 1000 mg/kg bw/day, from day 2 onwards.

Ophthalmoscopic examination revealed a treatment related bilateral coloration of the fundus oculi in 7/10 males and 4/10 females from the 300 mg/kg bw/day group and 9/9 males and 9/10 females from the 1000 mg/kg bw/day groups. Haematological and urinalysis results did not show any treatment related changes. At termination of the experiment, absolute and relative liver weights were slightly increased at the top dose of 1000 mg/kg bw/day, but there were no related histopathological findings. All other macroscopic and microscopic observations revealed no abnormalities related to the treatment.

The authors considered that the discoloration of the eye was due to the staining properties of the dye and was not of toxicological significance. They therefore concluded that 300 mg/kg bw/day was the "No Toxic Effect Level".

Ref.: 5 (subm I)

#### 3.3.5.2 Sub-chronic (90 days) toxicity (oral, dermal)

Guideline:	OECD 408
Species/strain:	Sprague-Dawley rats
Group size:	40 per sex (10 per sex and per dose)
Test substance:	IMEXINE FT (1-methylamino-2-nitro-5-(2,3-dihydroxypropyloxy)-benzene)
Batch:	Op. T107

## Opinion on 2-nitro-5-glyceryl methylaniline

---

Purity:	98.3%
Dose:	0, 50, 200 or 800 mg/kg bw/day
Route:	oral in 0.5% aqueous methylcellulose
Exposure:	daily for 13 weeks
GLP:	in compliance
Study period:	12 April 1994 – 15 July 1994

Three groups of 10 rats/sex received B060 daily by oral gavage at doses of 50, 200 or 800 mg/kg bw/day in 0.5% aqueous methylcellulose for 13 weeks. A control group of 10 rats/sex received the vehicle alone. Animals were observed twice daily for mortality/morbidity and once daily for clinical signs. Body weight and food and water consumption were recorded. Ophthalmologic evaluations on control and high-dose animals were performed before the exposure; all animals were examined during week 13. Haematology, clinical chemistry and urinalysis evaluations were performed on week 13. Any animal killed prematurely or found dead during the exposure was subjected to a macroscopic examination and tissues were preserved for microscopic evaluation. Animals were killed at the end of exposure, grossly examined and selected organs were weighed. All animals were subjected to a complete macroscopic examination. All macroscopic lesions and required tissues from animals in the control and high-dose groups were evaluated microscopically; macroscopic lesions and the pancreas, lungs, liver and kidneys were evaluated in all animals of the low and intermediate dose groups. Additionally, the adrenals of all males in the low and intermediate dose groups were evaluated.

#### Results

Mortality occurred in 7/10 males and 6/10 females at the group of 800 mg/kg bw/day. Histopathology of these animals revealed vacuolated pancreatic cells, tubular nephrosis and vacuolated renal tubular cells. Clinical signs consisted of ptialism at 200 and 800 mg/kg bw/day, soiled litter at 800 mg/kg bw/day and signs of poor clinical condition, including piloerection, hunched back, hypokinesia, swollen or hard abdomen, emaciation, dehydration and/or half-closed eyes in animals that died and in also surviving animals at 800 mg/kg bw/day. At all doses yellowish discolouration of urine, tail and body extremities indicate systemic exposure. Lower mean body weight gain in males and higher food consumption in both sexes were observed at 800 mg/kg bw/day. Body weight loss was limited to males at 800 mg/kg bw/day from week 8 to the end of the exposure. Bilateral opacity of the lens was noted in surviving animals at 800 mg/kg bw/day.

Bilateral yellowish colouration of the fundus oculi, attributed to the staining properties of the test substance, was noted in all surviving animals given 200 or 800 mg/kg bw/day.

Several clinical chemistry parameters were affected in surviving animals at the exposure level of 800 mg/kg bw/day. Higher absolute and relative kidney, adrenal and liver weights at 800 mg/kg bw/day were reported. Lower absolute and relative thymus and spleen weights at this dose level were attributed to stress and poor clinical condition. Enlarged or grey/green kidneys at 800 mg/kg bw/day correlated with tubular nephrosis and/or vacuolated tubular epithelium. Enlarged liver noted at 800 mg/kg bw/day correlated with higher organ weights, but had no microscopic changes. Enlarged adrenals in one male exposed to 800 mg/kg bw/day correlated with cortical cell vacuolation. Small thymuses and spleens at 800 mg/kg bw/day correlated with lower organ weights and lymphoid depletion observed microscopically. Blackish/brownish/reddish discolouration of the glandular stomach mucosa correlated with erosions observed microscopically in some animals. Histopathological changes reported consisted of vacuolated Langerhans islet cells in the pancreas and renal tubular epithelial cells, and tubular nephrosis at 800 mg/kg bw/day.

#### Conclusion

The NOAEL for this study was 200 mg/kg bw/day.

Ref.: 5

#### Comment



Bilateral coloration was reported in the fundus oculi in all animals at 1000 mg/kg bw/ 28 days and 7/10 males and 4/10 at 300 mg/kg bw 28 days. Bilateral opacity of the lens was seen at 800 mg/kg bw/90 days. Discoloration of the fundus oculi was seen at 200 and 800 mg/kg bw/90 days. Therefore, the SCCS considers the NOEL to be 50 mg/kg bw per day, and the NOAEL to be 200 mg/kg bw/d.

### 3.3.5.3 Chronic (> 12 months) toxicity

No data submitted

## 3.3.6 Mutagenicity / Genotoxicity

### 3.3.6.1 Mutagenicity / Genotoxicity in vitro

#### Submission III, 2005

##### Bacterial reverse mutation test, study 1

Guideline: /  
 Species/strain: *S. typhimurium*, TA98, TA100, TA1535, TA1537, TA1538  
 Replicates: Triplicate plates, only 1 test performed  
 Test substance: B 60  
 Solvent: DMSO  
 Batch: Batch op26  
 Purity: /  
 Concentrations: 10, 20, 50, 100, 250, 500, 1000, 2500 and 5000 µg/plate, with and without metabolic activation  
 Treatment: direct plate incorporation method  
 GLP: /

2-Nitro-5-glyceryl methylaniline has been investigated for gene mutation in *S. typhimurium* using the direct plate incorporation method, both with or without S9-mix. Liver S9 fraction from Aroclor 1254-induced rats was used as the exogenous metabolic activation system.

##### Results

No data on toxicity are available.

With or without S9-mix, no concentration related or biologically relevant increase in revertant numbers was observed, in any of the 5 *S. typhimurium* tester strains.

##### Conclusions

Based on the results and under the conditions of the assays performed, it was concluded that the test agent B 60 was negative in the *S. typhimurium* tester strains in the absence or presence of S9-mix

Ref.: 7 (submission I)

##### Comment

The study is of limited value for mutagenicity assessment, because the purity of the test substance was not given, no guidelines were followed, no quality insurance system was applied, and no independent repeat experiments were performed.

##### Bacterial reverse mutation test, study 2

Guideline: EC B14  
 Species/strain: *Salmonella typhimurium* TA98, TA100, TA1535 and TA1537; *Escherichia coli* WP2uvrA

Replicates:	triplicates in two independent experiments
Test substance:	Imexine FT
Solvent:	DMSO
Batch:	T 107
Purity:	98.3%
Concentrations:	312.5, 625, 1250, 2500 and 5000 µg/plate, without and with S9-mix
Treatment:	experiment 1: direct plate incorporation method with 48-72 h incubation, without and with S9-mix experiment 2: direct plate incorporation method with 48-72 h incubation, without S9-mix pre-incubation method with 60 minutes pre-incubation and 48 - 72 h incubation, with S9-mix
GLP:	in compliance
Study period:	March - September 1994

Imexine FT was investigated for the induction of gene mutations in *Salmonella typhimurium* and *Escherichia coli* (Ames test). Liver S9 fraction from Aroclor<sup>TM</sup>-induced rats was used as exogenous metabolic activation system. Test concentrations were based on the results of a preliminary toxicity test up to the prescribed maximum concentration of 5 mg/plate with TA100 both without and with S9-mix. Toxicity was evaluated on the basis of a reduction in the number of revertant colonies and/or qualitative evaluation of the bacterial background lawn. Experiment 1 and experiment 2 without S9-mix were performed with the direct plate incorporation method, experiment 2 with S9-mix with the pre-incubation method. Negative and positive controls were in accordance with the OECD guideline.

#### Results

Toxicity was only observed in TA1537 (1250 µg/plate and above) and in TA100 (5000 µg/plate) in experiment 1 without S9-mix. A reproducible, concentration dependent increase in the number of revertants was not found for any of the strains tested both in the presence and absence of S9 metabolic activation. A two-fold increase in revertants of strain TA1537 in the absence of S9-mix was not reproduced in the second experiment. An increase in revertants of strain TA1537 in the presence of S9-mix was not considered to be significant because the values achieved in the first test were within the historical control range of the laboratory and those of the second test were due to one plate which showed an aberrantly high value.

#### Conclusion

Under the experimental conditions used Imexine FT was not genotoxic (mutagenic) in the gene mutation tests in bacteria both in the absence and the presence of S9 metabolic activation.

Ref.: 6

#### Gene mutation assay in mammalian cells (*tk* locus)

Guideline:	OECD 476
Cells:	L5178Y <i>tk</i> <sup>+/-</sup> mouse lymphoma cells
Replicates:	single cultures in two independent experiments
Test substance:	2-nitro-5-glyceryl methylaniline (Imexine FT)
Solvent:	DMSO
Batch:	01221172
Purity:	98.4%
Concentrations:	Experiment 1: 500, 1000, 1200, 1400, 1600, 1800, 2000, 2200 and 2420 µg/ml without S9-mix 250, 500, 1000, 1200, 1400, 1600, 1800 and 2000 µg/ml with S9-mix

## Opinion on 2-nitro-5-glyceryl methylaniline

	Experiment 2: 250, 500, 1000, 1200, 1400, 1600, 1800, 2000, 2200 and 2420 µg/ml without S9-mix 250, 500, 1000, 1200, 1400, 1600, 1800, 2000, 2200 and 2420 µg/ml with S9-mix
Treatment	3 h both without and with S9-mix; expression period 2 days and a selection period of 11 days
GLP:	in compliance
Study period:	September - November 2004

2-nitro-5-glyceryl methylaniline was assayed for mutations at the *tk* locus of mouse lymphoma cells both in the absence and presence of metabolic activation. Test concentrations were based on the results of a cytotoxicity range-finding experiment measuring reduction in relative total growth compared to the concurrent vehicle control cell cultures. In the main test, cells were treated for 3 h followed by an expression period of 2 days to fix the DNA damage into a stable *tk* mutation. Liver S9 fraction from Arochlor 1254-induced rats was used as exogenous metabolic activation system. Toxicity was measured as percentage relative total growth (relative suspension growth of the cells over the 2-day expression period multiplied by the relative cloning efficiency at the time of selection). To discriminate between large (indicative for mutagenic effects) and small colonies (indicative for a clastogenic effect), colony sizing was performed. Negative and positive controls were in accordance with the OECD guideline.

#### Results

The appropriate level of toxicity (10-20% survival after the highest concentration) was almost reached (22-26%) in the absence of S9-mix and reached in the presence of S9-mix. Biological relevant increases in mutant frequency were observed in the absence of S9-mix at the two highest concentrations analysed in experiment 1 (2200 and 2420 µg/ml) and at the highest concentration (2420 µg/ml) evaluated in experiment 2. In the presence of S9-mix, obvious biological relevant and concentration-dependent increases in mutant frequency were observed in both experiments. Although increases in both small and large colony mutant frequencies were observed, there appeared to be a greater increase in the proportion of small-colony mutants.

#### Conclusion

Under the experimental conditions used 2-nitro-5-glyceryl methylaniline treatment did result in an increase of the mutant frequency at the *tk* locus of mouse lymphoma cells and, consequently, 2-nitro-5-glyceryl methylaniline is mutagenic in the mouse lymphoma assay.

Ref.: 7

#### Gene mutation assay in mammalian cells (*hprt* locus)

Guideline:	OECD 476
Cells:	L5178Y <i>tk</i> <sup>+/-</sup> mouse lymphoma cells
Replicates:	duplicate cultures in 3 independent experiments
Test substance:	2-nitro-5-glyceryl methylaniline (Imexine FT)
Solvent:	DMSO
Batch:	0122117
Purity:	98.4 %
Concentrations:	Experiment 1: 400, 800, 1200, 1400, 1600, 1800 and 2000 µg/ml without S9-mix 400, 800, 1200, 1400, 1600 and 1800 µg/ml with S9-mix
	Experiment 2: 400, 1200, 1600, 2000 and 2200 µg/ml without S9-mix 400, 800, 1400, 1600, 1800, 2000 and 2200 µg/ml with S9-mix
	Experiment 3: 400, 800, 1400, 1600, 1800 and 2000 µg/ml with S9-mix

Treatment 3 h both without and with S9-mix; expression period 7 days and a selection period of 12-13 days  
 GLP: in compliance  
 Study period: July – September 2005

2-nitro-5-glyceryl methylaniline was assayed for mutations at the *hprt* locus of mouse lymphoma cells both in the absence and presence of metabolic activation. Test concentrations were based on the results of a cytotoxicity range-finding experiment measuring reduction in relative survival compared to the concurrent vehicle control cell cultures. In the main test, performed according the microtitre<sup>R</sup> fluctuation technique, cells were treated for 3 h followed by an expression period of 7 days to fix the DNA damage into a stable *hprt* mutation. Liver S9 fraction from Arochlor 1254-induced rats was used as exogenous metabolic activation system. Toxicity was measured as percentage relative survival. Negative and positive controls were in accordance with the OECD guideline.

### Results

In experiment 1 and experiment 2 with S9-mix the appropriate level of toxicity (10-20% survival after the highest concentration) was reached. In experiment 2 without S9-mix and in experiment 3 survival was higher than the appropriate level.

In experiment 1 and 2 in the absence of S9-mix, a biological relevant increases in mutant frequency was not observed following treatment with 2-nitro-5-glyceryl methylaniline. A weak trend was observed in the second experiment but no statistically significant increases in mutant frequency were observed at any concentration tested and the effect was not reproduced between experiments. Therefore this increase was not considered biologically relevant.

In the presence of S9-mix when tested up to toxic concentrations, statistically significant increases in mutant frequency were observed at two intermediate concentrations (1200 and 1400 µg/ml) in experiment 1 and at the highest concentration (2200 µg/ml) analysed in experiment 2. Linear trends were observed in both experiments. In experiment 1, the mean mutant frequency values observed at both concentrations where a statistically significant response was observed and those at 800 and 1800 µg/ml exceeded the upper limit of the historical control range. In experiment 3, performed with S9-mix to confirm the results from experiment 1 and 2, a biological relevant increase in mutant frequency was not observed. Overall, In the presence of S9-mix, 2-nitro-5-glyceryl methylaniline showed evidence of increased mutant frequency in two experiments but these effects were not reproduced in a third experiment. The evaluation criteria for a positive result were not fulfilled and these increases were considered of little or no biological relevance.

### Conclusion

It was concluded that 2-nitro-5-glyceryl methylaniline (B060) did not induce mutations at the *hprt* locus of L5178Y mouse lymphoma cells in two independent experiments in the absence of rat liver S9 mix when tested under the conditions employed in this study.

Ref.: 8

### Comment

Two of three independent tests in the presence of S-9 mix were positive, with a concentration-dependent effect. Given the positive result in the mouse lymphoma tk<sup>+/-</sup> test, the SCCP considers this test inconclusive/equivocal. The possibility that 2-nitro-5-glyceryl methylaniline has the potential to induce gene mutations in cultured mammalian cells cannot be excluded based on this test/the two mammalian cell gene mutation tests.

### ***In vitro* mammalian chromosomal aberration test, study 1**

Guideline: /  
 Species/strain: Chinese hamster ovary (CHO) cells  
 Replicates: Duplicate cultures but no repeat experiment

Test substance: 2-Nitro-5-glyceryl methylaniline  
 Solvent: DMSO  
 Batch: /  
 Purity: /  
 Concentrations: Preliminary concentration range finding study: No raw data given  
 Test without S9-mix: 0, 0.5, 1, 2 and 4 mg/ml  
 Test with S9-mix: 0, 0.5, 1, 2 and 4 mg/ml  
 GLP: /

2-Nitro-5-glyceryl methylaniline has been investigated for induction of chromosomal aberrations in CHO cells. The test concentrations were established from a preliminary toxicity study. Liver S9 fraction from Aroclor 1254-induced rats was used as the exogenous metabolic activation system. Samples were exposed during 1 hour with or without S9-mix. Cultures were kept for 19 hours before harvest.

#### Results

For toxicity no raw data were given. While both with and without S9-mix a slight concentration dependent trend of aberrations was found, no statistics have been used to evaluate the incidence of aberrant cells. A significant increase in the aberration rate was observed as compared to the corresponding solvent control, mainly in the absence of activation.

#### Conclusions

Under the conditions of the study clastogenic effects were observed

Ref.: 8 (submission I)

#### Comments

No statistics were performed. The treatment time was short (1 h), the exposure and expression period are inadequately selected, the test substances was not characterised (batch and purity not specified). As the assay was not performed according to modern standard strategies and guidelines, the results are considered inadequate.

### ***In vitro* mammalian chromosomal aberration test, study 2**

Guideline: OECD 473, EC B10  
 Species/strain: Chinese hamster ovary (CHO) cells  
 Replicates: Duplicate cultures, single experiment  
 Test substance: 2-nitro-5-glyceryl methylaniline, Imexine FT  
 Solvent: DMSO  
 Batch: Batch No 0503126  
 Purity: /  
 Concentrations: 407, 1694 and 2420 µg/ml without metabolic activation  
 1186, 1694 and 2420 µg/ml with metabolic activation  
 GLP: in compliance

2-nitro-5-glyceryl methylaniline has been investigated for induction of chromosomal aberrations in CHO cells. Liver S9 fraction from Aroclor 1254-induced rats was used as the exogenous metabolic activation system.

The analysed test concentrations were selected from the range of treatment concentrations based on the cytotoxicity observed. With respect to the molecular weight of 2-nitro-5-glyceryl methylaniline, the maximum concentration tested was 2420 µg/ml (corresponding to 10 mM). Cells were treated for 3 h (without and with S9-mix) and harvested 20 h after the start of treatment.

## Results

On the post-treatment medium, no marked influence on the pH or osmolarity was noted as compared to the concurrent vehicle controls.

A 68 % reduction of the mitotic index was noted in the absence of activation at the top concentration level (2420 µg/ml). With S9 mix, at the top concentration the mitotic index reduction was 31% of the control.

Without activation system a significant and biologically relevant increase in the number of cells with structural chromosomal aberrations was noted at the top concentration of 2420 µg/ml (2420 µg/ml 14 %). With activation system a statistically and/or biologically significant concentration-dependent relevant increase in the number of aberrant cells was observed as compared to the corresponding solvent control at the top concentration of 2420 µg/ml (2420 µg/ml 13.5%).

Without and with activation system a relevant increase in the number of polyploid metaphases was recorded at the top concentration. In addition, many endoreduplicated cells were observed in the presence of the activation system.

## Conclusions

IMEXINE FT induced chromosomal aberrations in Chinese hamster ovary cells in the absence and presence of metabolic activation, under the conditions of this test.

Ref.: 11 (submission I)

## Comment:

The increase in the number of polyploid metaphases found at the top concentration may be an indication of aneugenicity.

## ***In vitro* unscheduled DNA synthesis test in human HeLa cells**

Guideline:	/
Cells:	Hela S3 cells
Replicates:	triplicates in two independent experiments
Test substance:	3389 Pan
Solvent:	DMSO
Batch:	BL VII P 108
Purity:	/
Concentrations:	Experiment 1: 0.156, 0.313, 0.625, 1.25 and 2.50 mg/ml without S9-mix 0.313, 0.625, 1.25, 2.50 and 5.0 mg/ml with S9-mix
Treatment	3 h treatment
GLP:	in compliance
Study period:	April – December 1985

3389 Pan was investigated for the induction of unscheduled DNA synthesis (UDS) in human HeLa cells. Test concentrations were based on the results of a cytotoxicity assay on cell viability, cell detachment and signs of gross toxicity. Cells were treated for 3h with 5µCi <sup>3</sup>H-thymidine and then progressed for autoradiography. The induction of UDS has been measured by liquid scintillation counting. Liver S9 fraction from phenobarbitone/β-naphthoflavone-induced rats was used as the exogenous metabolic activation system. 4-nitroquinoline-N-oxide and benzo[a]pyrene were used as positive control.

## Results

In the absence of metabolic activation, the incorporation of <sup>3</sup>H-thymidine was similar to that of negative controls at the three lowest treatment levels. At 1.25 and 2.50 mg/ml, incorporation levels declined to approximately 90% and 50% of the control levels, respectively. In the presence of metabolic activation, the incorporation of <sup>3</sup>H-thymidine decreased in a concentration-dependent manner. At 5.00 mg/ml, incorporation was approximately 30% of control levels.

**Conclusion**

Under the experimental conditions used 3389 Pan treatment did not result in an increase in unscheduled DNA synthesis and, consequently, 3389 Pan is not genotoxic in this UDS test in human Hela cells.

Ref.: 9

**Comment**

According to the modern standard strategies and guidelines, this assay is unsuitable for evaluation. UDS measured by a liquid scintillation counter is not an established test system and may not be very sensitive. Therefore, the results have limited value in assessing the genotoxicity of the test substance. The purity of the test substance is not reported.

Moreover, the report contains a number of inconsistencies and omissions:

- There are two summaries: "summary and conclusion" on the back side of the front page and "1 summary" on page 1 of the report.
- Both in the summaries and in the description of the "4.3 main assay (UDS)" it is stated that the highest concentration to be tested was 2.50 mg/ml in the presence and absence of metabolic activation, while the data table for UDS in the presence of metabolic activation indicates that the highest concentration tested was 5.00 mg/ml.
- The numbering of the tables containing the assay results does not correspond to the description in the results section.
- detailed results are not given for a second experiment described in the results section.

3.3.6.2 Mutagenicity / Genotoxicity *in vivo***Submission IV, 2009****Unscheduled DNA Synthesis (UDS) Test with Mammalian Liver Cells *In Vivo***

Guideline:	OECD 486 (1997)
Species/strain:	rat (Wistar)
Group size:	4 male rats/dose/treatment group
Test substance:	2-nitro-5-glyceryl methylaniline
Batch:	0140514
Purity:	99.9% (HPLC 234 nm)
Vehicle:	1.0% carboxymethylcellulose (CMC)
Dose level:	0, 875 and 1750 mg/kg bw
Route:	oral gavage, one single dose
Sacrifice times:	4 and 16 hours after treatment
GLP:	in compliance
Study period:	2 March 2009 – 7 May 2009

2-nitro-5-glyceryl methylaniline was investigated for the induction of unscheduled DNA synthesis (UDS) in hepatocytes of rats. Test concentrations were based on the results of a pre-experiment on acute toxicity. Rats were treated orally under identical conditions as in the main UDS test with doses up to 2000 mg/kg bw and examined for acute toxic symptoms at various intervals of 1, 2-4, 6, and 24 h after start of treatment. In the main experiment 4 male mice per dose and treatment time were exposed orally to 0, 875 and 1750 mg/kg bw. The volume administered orally was 10 ml/kg bw. The rats of all dose groups were examined for acute toxic symptoms at intervals of around 1, 2, 4 (4 h sacrifice only), and 16 h (16 h sacrifice only).

Hepatocytes for UDS analysis were collected approximately 4 h and 16 h after administration of 2-nitro-5-glyceryl methylaniline. At least 90 minutes after plating the cells were incubated for 4 h with 5 µCi/ml <sup>3</sup>H-thymidine (specific activity 20 Ci/mmol) followed by overnight incubation with unlabelled thymidine. Evaluation of autoradiography was done after 14 days. UDS was reported as nuclear and cytoplasmic grain counts as well as net

nuclear grain counts: the nuclear grain count subtracted with the number of grains in the most heavily labelled nuclear sized cytoplasmic area adjacent to each nucleus. Moreover, the percentage of cells in repair (defined as cells with a net grain count of at least +5) was calculated for each animal. Unscheduled synthesis was determined in 50 randomly selected hepatocytes on 2 replicate slides per rat from at least 3 treated rats. Negative and positive controls were in accordance with the OECD guideline.

#### Results

The viability of the hepatocytes was not substantially affected by the treatment with 2-nitro-5-glyceryl methylaniline at any of the treatment periods or dose groups. The inter-individual variations obtained for the yield and the viability of the isolated hepatocytes were in the range of the historical laboratory control.

In the pre-experiment on acute toxicity, reduction of spontaneous activity, ruffled fur and orange stained urine was seen at 1750 and 2000 mg/kg bw 2-nitro-5-glyceryl methylaniline up to 24 h after exposure. At the highest dose tested (2000 mg/kg bw) one rat died. Consequently, the maximum tolerated dose level of 1750 mg/kg bw was chosen to be suitable as top dose for the main experiment. Also, in the main experiment reduction of spontaneous activity, ruffled fur and coloured urine was reported after 2-nitro-5-glyceryl methylaniline exposure (particularly in the 1750 mg/kg bw group). One rat died in the 1750 mg/kg bw dose group 16 h after treatment. The coloured urine of rats treated with 2-nitro-5-glyceryl methylaniline confirms its bioavailability and systemic distribution.

Neither a biologically relevant increase in mean net nuclear grain count nor in the percentage of cells in repair as compared to the untreated control was found in hepatocytes of any treated animal both for the 4 h and the 16 h treatment time.

#### Conclusion

Under the experimental conditions reported 2-nitro-5-glyceryl methylaniline did not induce DNA damage leading to unscheduled DNA synthesis and, consequently, is not genotoxic in rats in the *in vivo* UDS test.

Ref.: 19 (subm IV)

### Submission III, 2005

#### Mammalian erythrocyte micronucleus test, study 1

Guideline:	/
Species:	Albino Swiss mouse
Group sizes:	6 males per dose, 5 control animals
Substance:	B60
Batch:	DG1
Purity:	/
Dose levels:	0, 350, 450 and 550 mg/kg bw/day in a volume of 10 ml/kg bw
Route:	intraperitoneal injection
Administration:	2 intraperitoneal injections, 24 hours apart
Vehicle:	DMSO
Sacrifice times:	after 24, 48 and 72 hours
GLP:	/

2-Nitro-5-glyceryl methylaniline has been investigated for induction of micronuclei in the bone marrow cells of male mice. Dose levels were determined on the basis of the results of a preliminary dose-range finding study indicating that the LD50 is 650 mg/kg bw.

2-Nitro-5-glyceryl methylaniline dissolved in DMSO was administered by 2 single intraperitoneal injections with 24 h interval of 0, 350, 450 and 550 mg/kg bw/day to male mice. One sacrifice time was selected: 6 hours after last dosing. Bone marrow smears were obtained from the positive control group 24 after dosing.



A total of at least 2000 erythrocytes were examined from each animal; the incidence of micronucleated erythrocytes and the ratio of polychromatic erythrocytes to normochromatic erythrocytes were calculated. Negative and positive controls were in accordance with the OECD guideline.

#### Results

Toxic effects such as passivity, dyspnea and ataxia were observed in all dosage groups. No statistically significant or biologically relevant increase in the incidence of micronucleated polychromatic cells over the concurrent vehicle control values were observed at any sampling time. No significant variations in the ratio of normochromatic to polychromatic erythrocytes, which would have indicated that the bone marrow was reached by the test material and or toxicity of the latter, were noted.

#### Conclusions

Under the test conditions, 2-nitro-5-glyceryl methylaniline did not induce micronuclei in the bone marrow of mice.

Ref.: 9 (submission I)

#### Comments

The test did not conform to OECD guidelines or GLP conditions. Only one experiment was performed, and the number of animals per dose was insufficient. The test is considered inadequate.

### **Mammalian erythrocyte micronucleus test, study 2**

Guideline:	OECD 474 (1997)
Species:	Swiss Ico: OF1(IOPS caw) mice
Group size:	5 males and 5 females
Test substance:	Imexine FT (2-nitro-5-glyceryl methylaniline)
Batch:	0504494
Purity:	/
Dose levels:	0, 500, 1000 and 2000 mg/kg bw
Administration:	2 intragastric gavages on 2 consecutive days (24-hours interval)
Solvent:	1 % methylcellulose
Sacrifice times:	24 hours after the last dosing.
GLP:	in compliance
Study period:	12 March – 20 April 2001

Imexine FT has been investigated for induction of micronuclei in the bone marrow cells of male and female mice. Dose levels were determined by a preliminary range finding study in which no toxic effects were seen. The substance was administered by two single intragastric gavages at 24-hours interval and the animals sacrificed 24 hours after the last administration. 2-nitro-5-glyceryl methylaniline in 1 % methylcellulose, batch 0504494 (purity not stated was administered by 2 single oral doses at 24-hours intervals.

One sacrifice time was selected: 24 h after the last oral administration. Bone marrow smears were obtained from the positive control group 24 hours after dosing.

A total of at least 1000 erythrocytes were examined from each animal; the incidence of micronucleated erythrocytes and the ratio of polychromatic erythrocytes to normochromatic erythrocytes were calculated. Negative and positive controls were in accordance with the OECD guideline.

#### Results

No statistically significant or biologically relevant increase in the incidence of micronucleated polychromatic cells over the concurrent vehicle control values were observed for any dosage groups. No significant reduction in the PCE/NCE ratio was observed in any of the dosage groups of mice treated with Imexine FT.

### Conclusions

Under the conditions of the test it can be concluded that Imexine FT in doses at which no significant variation in the PCE/NCE ratio was observed, does not induce statistically significant increase in the frequency of PCE.

Ref.: 12 (submission I)

### Comment:

There are no indications that the target cells were exposed as treatment with Imexine FT did not result in a decrease of the PCE/NCE ratio. Moreover, it should be noted that a trend to a dose response was observed and that there is large inter-individual variations in the individual values. The test is of limited value.

### Mouse bone marrow micronucleus test, study 3

Guideline:	OECD 474
Species/strain:	Swiss Ico; OF1 (IOPS Caw) mice
Group size:	5 mice/sex/dose group
Test substance:	Imexine FT
Batch no:	0504494
Purity:	98%
Dose level:	500, 1000 and 2000 mg/kg bw
Route:	oral
Treatment:	2 applications 24 h apart
Vehicle:	1% aqueous methylcellulose
Sacrifice times:	24 h after the last treatment.
GLP:	in compliance
Study period:	February – May 2001

Imexine FT has been investigated for the induction of micronuclei in bone marrow cells of mice. Test concentrations were based on the results of a preliminary toxicity test in male and female mice on clinical signs and mortality for a period of 48 h. In the main experiment mice received orally two treatments of 0, 500, 1000 and 2000 mg/kg bw 24 h apart. Bone marrow cells were collected 24 h after the last dosing. Toxicity and thus exposure of the target cells was determined by measuring the ratio between polychromatic and normochromatic erythrocytes (PCE/NCE). Bone marrow preparations were stained with Giemsa and examined microscopically for the PCE/NCE ratio and micronuclei. Negative and positive controls were in accordance with the OECD guideline.

### Results

Both in the preliminary study and the main experiment, no mortality and no clinical signs were observed. Treatment with Imexine FT did not result in decreased PCE/NCE ratios compared to the untreated controls. Biological relevant increases in the number of micronucleated PCEs compared to the concurrent vehicle controls were not found at any dose tested.

### Conclusion

Under the experimental conditions used Imexine FT did not induce micronuclei in bone marrow cells of treated mice and, consequently, Imexine FT was not genotoxic (clastogenic and/or aneugenic) in bone marrow cells of mice.

Ref.: 10

### Comment

Since treatment with Imexine FT did not result in a decrease of the PCE/NCE ratio and there were no other indications of bone marrow exposure, the test is of limited value.

#### Mouse bone marrow micronucleus test, study 4

Guideline:	OECD 474 (1997)
Species/strain:	CrI:CD-1 <sup>®</sup> (ICR)BR mice
Group size:	5 mice/sex/dose group
Test substance:	2-nitro-5-glyceryl methylaniline
Batch no:	0122117
Purity:	98.4 %
Dose level:	250, 500 and 1000 mg/kg bw
Route:	oral gavage
Vehicle:	0.5 % methylcellulose
Sacrifice times:	24 h after treatment for all concentrations, 48 h for the control and highest dose group only.
GLP:	in compliance
Study period:	November 2004 - June 2005

2-nitro-5-glyceryl methylaniline has been investigated for the induction of micronuclei in bone marrow cells of mice. Test concentrations were based on the results of a dose range-finding study in male and female mice on toxic signs and mortality. In the main experiment mice were exposed by gavage to single doses of 0, 250, 500 and 1000 mg/kg bw. Mice were examined immediately and 1 h after dosing and at least daily for the duration of the experiment for signs of clinical toxicity and mortality. Bone marrow cells were collected 24 h or 48 h (control and high dose only) after dosing. Toxicity and thus exposure of the target cells was determined by measuring the ratio between polychromatic and normochromatic erythrocytes (PCE/NCE). An additional satellite group of 6 male and 6 female mice, treated with 1000 mg/kg bw, was included for determination of plasma concentrations of the test article. Blood was collected at 1 and 4h after dosing (3 mice/sex/per timepoint). Bone marrow preparations were stained with acridine orange and examined microscopically for the PCE/NCE ratio and micronuclei. Negative and positive controls were in accordance with the OECD guideline.

#### Results

In the range-finding study clinical signs were noted in animals given 1000 and 2000 mg/kg bw 2-nitro-5-glyceryl methylaniline from the 1<sup>st</sup> hour post-dosing upwards, including hypoactivity, irregular respiration, squinted eyes, and orange discoloration of ears and tail. On day 1 after treatment, these clinical observations persisted or increased in the high dose group. Based on these results, the maximum tolerated dose was estimated to be 1000 mg/kg bw and this dose level was used as the high dose in the main study.

No mortality occurred during the study. All animals in all doses groups showed hypoactivity, discoloured ears, tails and limbs and squinted eyes at 1 hour post-dosing. On day 1 after treatment, these signs had disappeared.

Treatment with 2-nitro-5-glyceryl methylaniline did not result in decreased PCE/NCE ratios compared to the untreated controls. However, plasma analysis confirmed the systemic exposure of the test animals to the compound (mean  $C_{max}$   $54.3 \pm 15.3$   $\mu\text{g/ml}$  at 1 h post dosing in males and females given 1000 mg/kg bw).

Biological relevant increases in the number of micronucleated bone marrow cells compared to the concurrent vehicle controls were not found at any dose tested, neither 24 nor 48 h after treatment.

#### Conclusion

Under the experimental conditions used 2-nitro-5-glyceryl methylaniline did not induce micronuclei in bone marrow cells of treated mice and, consequently, 2-nitro-5-glyceryl methylaniline was not genotoxic (clastogenic and/or aneugenic) in bone marrow cells of mice.

Ref.: 11

**3.3.7 Carcinogenicity**

No data submitted

**3.3.8 Reproductive toxicity****3.3.8.1 Two generation reproduction toxicity**

No data submitted

**3.3.8.2 Teratogenicity**

Guideline:	OECD 414
Species/strain:	Sprague-Dawley rats
Group size:	mated rats in four groups (n=36, n=33, n=40, n=34)
Test substance:	IMEXINE FT
Batch:	Op. 8
Purity:	99.9%
Dose:	0, 100, 300, 1000 mg/kg bw/day
Route:	oral gavage
Vehicle:	0.5% aqueous carboxymethylcellulose
Exposure:	from day 6 through day 15 of gestation
GLP:	in compliance
Date:	23 October 1990 – 17 January 1991

Three groups of mated rats received B060 by oral gavage at doses of 100 (n=33), 300 (n=40) or 1000 mg/kg bw/day (n=34) in 0.5% aqueous carboxymethylcellulose from day 6 through day 15 of gestation. A control group of 36 mated rats received the vehicle only. The day of mating was designated as day 0 of gestation. Animals were observed twice daily for mortality/morbidity. Clinical signs were checked once daily. Food consumption and body weight were recorded. On day 20 of gestation, the animals were killed and examined macroscopically. Foetuses were removed by Caesarean section. The following litter parameters were recorded: number of corpora lutea, number of implantation sites, number and distribution of early and late resorptions, and number and distribution of dead and live foetuses. Foetuses were weighed, sexed and examined for possible external abnormalities. The first twenty litters of each group were examined for soft tissue and skeletal examinations.

**Results**

One 300 mg/kg bw/day female was found dead on day 17 as a result of gavage accident. At 1000 mg/kg bw/day, one female showed reddish nasal discharge and piloerection on days 9 and 10 and was sacrificed moribund on day 10. The stomach of this animal had ulcerated foci; yellow discolouration was present in the stomach, liver, skin, and kidneys. Lemon-coloured urine was observed in almost all treated animals from day 7 to day 16. No abortions were observed. Maternal body weight gain and food consumption at 1000 mg/kg bw/day were slightly lower than control group values; however, these changes were not statistically significant. No other compound-related findings were observed in dams at any dose level.

One dead foetus and an increase in the number of foetuses with unossified 4<sup>th</sup> metacarpals were observed at 1000 mg/kg bw/day. No other compound-related anomalies or malformations of toxicological significance were observed.

**Conclusion**

The NOAEL for materno-toxicity for this study was 300 mg/kg bw/day, while the NOAEL for embryo-toxicity/teratogenicity was 1000 mg/kg bw/day.

Ref.: 12

#### Conclusion from previous opinion

**Dams:** no treatment related mortalities were observed. One mortality in the 300 mg/kg bw/day group was attributed to a gavaging error. All treated animals presented lemon coloured urine from day 7 to day 16. One female (1000 mg/kg bw/day) was culled following observation of a reddish nasal discharge and piloerection on days 9 and 10 post-coitum. At necropsy, most organs of the culled dam were stained yellow and the stomach showed some ulcerated foci. No abortions were reported.

Maternal body weight gain and food consumption were slightly reduced in the highest dose group compared to the control group. No abnormalities were recorded at necropsy. No changes were noted in the other treated groups.

**Foetuses:** Litter parameters were comparable between the control and treated groups. External examination revealed no treatment-related foetal malformations. No soft tissue malformations were observed. The only skeletal malformation noted was the number of foetuses from the 1000 mg/kg bw group with a delayed ossification of the fourth metacarpus when compared to controls. This observation was considered by the authors to be related to the slight maternotoxicity seen in this group.

The study authors concluded that, at 300 mg/kg bw/day, there was no evidence of maternal toxicity, embryotoxicity or teratogenicity, whereas the 1000 mg/kg bw/day dose level was slightly maternotoxic but neither embryotoxic nor teratogenic.

#### Comment

The study was re-assessed and the conclusion from the previous opinion was confirmed.

### **3.3.9 Toxicokinetics**

No data submitted

### **3.3.10 Photo-induced toxicity**

#### 3.3.10.1 Phototoxicity / photoirritation and photosensitisation

No data submitted

#### 3.3.10.2 Phototoxicity / photomutagenicity / photoclastogenicity

No data submitted

### **3.3.11 Human data**

No data submitted

### **3.3.12 Special investigations**

No data submitted

**3.3.13 Safety evaluation (including calculation of the MoS)****CALCULATION OF THE MARGIN OF SAFETY****2-Nitro-5-glyceryl methylaniline****Oxidative**

<b>Absorption through the skin</b>	<b>A</b>	<b>=</b>	<b>4.11 µg/cm<sup>2</sup></b>
<b>Skin Area surface</b>	<b>SAS</b>	<b>=</b>	<b>580 cm<sup>2</sup></b>
<b>Dermal absorption per treatment</b>	<b>SAS x A x 0.001</b>	<b>=</b>	<b>2.38 mg</b>
<b>Typical body weight of human</b>		<b>=</b>	<b>60 kg</b>
<b>Systemic exposure dose</b>	<b>SAS x A x 0.001/60</b>	<b>=</b>	<b>0.04 mg/kg bw/d</b>
<b>No Observed Adverse Effect Level (13 weeks, oral, rats)</b>	<b>NOAEL</b>	<b>=</b>	<b>200 mg/kg bw/d</b>
<b>Corrected for bio-availability (50 %)*</b>			<b>100 mg/kg bw/d</b>

<b>MOS</b>	<b>=</b>	<b>2500</b>
------------	----------	-------------

**Non oxidative conditions**

<b>Absorption through the skin</b>	<b>A</b>	<b>=</b>	<b>1.12 µg/cm<sup>2</sup></b>
<b>Skin Area surface</b>	<b>SAS</b>	<b>=</b>	<b>580 cm<sup>2</sup></b>
<b>Dermal absorption per treatment</b>	<b>SAS x A x 0.001</b>	<b>=</b>	<b>0.65 mg</b>
<b>Typical body weight of human</b>		<b>=</b>	<b>60 kg</b>
<b>Systemic exposure dose</b>	<b>SAS x A x 0.001/60</b>	<b>=</b>	<b>0.011 mg/kg bw/d</b>
<b>No Observed Adverse Effect Level (13 weeks, oral, rats)</b>	<b>NOAEL</b>	<b>=</b>	<b>200 mg/kg bw/d</b>
<b>Corrected for bio-availability (50 %)*</b>			<b>100 mg/kg bw/d</b>

<b>MOS</b>	<b>=</b>	<b>9090</b>
------------	----------	-------------

\* standard procedure according to the SCCS's Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation

**3.3.14 Discussion***Physico-chemical properties*

2-Nitro-5-glyceryl methylaniline is used in semi permanent hair colouring products at a maximum concentration of 1%. The formulation is applied as such without any further dilution. 2-Nitro-5-glyceryl methylaniline is a secondary amine, and thus, prone to nitrosation. It should not be used in combination with nitrosating agents. The nitrosamine content should be < 50 ppb. The nitrosamine content in the test materials was not reported. The stability of 2-Nitro-5-glyceryl methylaniline in typical hair dye formulations was not reported.

*General toxicity*

The maximal non-lethal dose of 2-nitro-5-glyceryl methylaniline was higher than 1000 mg/kg bw but lower than 2000 mg/kg bw after a single oral administration in fasted rats. In a 13-week oral study, bilateral coloration was reported in the fundus oculi in all animals at 1000 mg/kg bw/ 28 days and 7/10 males and 4/10 at 300 mg/kg bw 28 days. Bilateral opacity of the lens was seen at 800 mg/kg bw/90 days. Discoloration of the fundus oculi

was seen at 200 and 800 mg/kg bw/90 days. Therefore, the SCCS considers the NOEL to be 50 mg/kg bw per day, and the NOAEL to be 200 mg/kg bw/d. The NOAEL for materno-toxicity was set at 300 mg/kg bw/day, while the NOAEL for embryo-toxicity/teratogenicity was set at 1000 mg/kg bw/day.

#### *Irritation / sensitisation*

The test substance was considered as non-irritant to rabbit skin when applied as a 1% suspension in 1,2-propanediol. The 1% suspension caused some slight and transient irritation of the rabbit eye.

The highest concentration tested (10%) in the LLNA was considered too low. No conclusion regarding the sensitising potential of 2-nitro-5-glyceryl methylaniline can be drawn.

#### *Dermal absorption*

In oxidative conditions, the mean + SD: 4.11 µg/cm<sup>2</sup> (2.39 + 1.72) is used for the calculation of the Margin of Safety.

In non-oxidative conditions, too few chambers were used. The mean + 2 standard deviations (1.01 µg/cm<sup>2</sup> (0.51 + 2 × 0.25)), corrected for the use of a lower concentration (0.9 instead of 1.0%)  $1.01 \times 10/9 = 1.12$  µg/cm<sup>2</sup> is used for the calculation of the Margin of Safety under non-oxidative conditions.

It should be noted that the dermal absorption under non-oxidative conditions was significantly lower than under oxidative conditions, which is unusual.

#### *Mutagenicity / genotoxicity*

Overall, the genotoxicity of 2-nitro-5-glyceryl methylaniline (Imexine FT) has been investigated for the three types of mutations: gene mutations, chromosome aberrations and aneuploidy.

Treatment with 2-nitro-5-glyceryl methylaniline did not result in an increase in the mutant frequency in bacteria. In the mouse lymphoma assay 2-nitro-5-glyceryl methylaniline induced an increase in the mutant frequency at the *tk*-locus. Although increases in both small and large colony mutant frequencies were observed, there appeared to be a greater increase in the proportion of small-colony mutants, indicating to a clastogenic next to a mutagenic effect. A second gene mutation assay in mammalian cells using the same cell line but the *hprt* locus as reporter gene was considered not to be of relevance by the study authors but inconclusive/equivocal by the SCCS. The possibility that 2-nitro-5-glyceryl methylaniline has the potential to induce gene mutations in cultured mammalian cells cannot be excluded based on this test/the two mammalian cell gene mutation tests.

In a poorly performed *in vitro* unscheduled DNA synthesis test 2-nitro-5-glyceryl methylaniline was negative. The putative clastogenic effect was confirmed in two poorly performed *in vitro* chromosome aberration tests.

The positive *in vitro* results with 2-nitro-5-glyceryl methylaniline could not be confirmed in *in vivo* assays. The positive/equivocal findings in the *in vitro* gene mutation assays were not endorsed by an *in vivo* unscheduled DNA synthesis tests. The clastogenic effects found in the *in vitro* studies could not be affirmed in *in vivo* experiments covering the same endpoint. In four (3 poorly and one well performed) mouse bone marrow micronucleus tests, following oral and i.p. administration, 2-nitro-5-glyceryl methylaniline was negative. Consequently, 2-nitro-5-glyceryl methylaniline can be considered to have no *in vivo* genotoxic potential and additional tests are unnecessary.

#### *Carcinogenicity*

No data submitted

#### 4. CONCLUSION

The SCCS is of the opinion that the use of 2-Nitro-5-glyceryl methylaniline, at a maximum on-head concentration of 0.8% in oxidative and of 1.0% in non-oxidative hair dye formulations does not pose a risk to the health of the consumer.

2-Nitro-5-glyceryl methylaniline is a secondary amine, and thus, prone to nitrosation. It should not be used in combination with nitrosating agents. The nitrosamine content should be < 50 ppb.

A sensitisation potential of 2-nitro-5-glyceryl methylaniline cannot be excluded.

#### 5. MINORITY OPINION

Not applicable

#### 6. REFERENCES

##### Submission IV, supplement 2011

1. Waye Keuong Y. (2011) Stability of 2-nitro-5-glyrecyl methylaniline (B060) under oxidative conditions. L'Oréal, Analytical Department, F-92110 Clichy La Garenne. 21.10.2011

##### Submission IV, 2009

*References in italics, consisting of documents and study reports already submitted to the SCCP (Submission III, 2005) or scientific papers are not submitted as full reports in the present dossier. They can be provided upon request.*

1. *G. Sire. Evaluation of Skin Sensitization Potential in Mice using the Local Lymph. Node Assay (LLNA). CIT Study No. 27941 TSS, 2005*
2. *National Institute of Environmental Health Sciences. The murine local lymph node Assay: A test method for assessing the allergic contact dermatitis potential of chemicals/compounds: The results of an independent peer review evaluation coordinated by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National Toxicology Program Center for Evaluation of Alternative Toxicological Methods (NICETAM). NIH Publication, 1999, No 99-4494*
3. *Upadhye M.R, Maibach H.I.. Influence of area of application of allergen on sensitization in contact dermatitis. Contact Dermatitis, 1992, 27: 281-286*
4. *R.A.F de Ligt. In Vitro percutaneous absorption of [<sup>14</sup>C]-2-nitro-5-glyceryl-methylaniline through human skin membranes under oxidative conditions. TNO Study No. 8240, Report No. V8240, 2009.*
5. *R.A.F. de Ligt. In Vitro Percutaneous Absorption of [<sup>14</sup>C]-nitro-3-glyceryl-methylaniline through human skin membranes using flow-through diffusion cells. TNO Study No. 6218, 2005*
6. *C. Fabreguettes. 13-Week Toxicity Study by Oral Route in Rats. CIT Study No. 11389 TCR (CIES1 94022), 1995*
7. *SCCP's Note of Guidance for the testing of cosmetic ingredients and their safety evaluation. 6<sup>th</sup> revision. 19 December 2006*
8. *Mutagenic Evaluation of the Compound l-Methylamino-2-nitro-5-(2,3-dihydroxypropyloxy)-benzene (Ref: op 26) in Ames Salmonella Typhimurium Plate*



- Test*. L'OREAL, Department of Chemical Protection and Photobiological Research in Vitro, Advanced Research Center, Aulnay, - France. Report of 2.6.86, rev. 6.2.1992.
9. Evaluation of Compound 3-Methylamino-4-Nitrophenyl-Dihydroxy Propylether in the Chromosome Aberration Test with Chinese Hamster Ovary Cells (*in vitro*). University of Leiden - NL. Departm of Radiation Genetics and Chemical Mutagenesis. 27.7.87.
  10. 2-Nitro-5-glyceryl methylaniline: induction of chromosome aberrations in cultured Chinese hamster Ovary (CHO) cells. Covance Laboratories Study n° 413/37, 2000
  11. Test du Micronoyau sur Moelle Osseuse de Souris Traitée *in vivo* par Voie Intrapéritonéale. Produit testé B 60, 1-Méthylamino-2-Nitro-5(2,3-Dihydroxypropyloxy)-Benzène. L'OREAL, Département des "Contrôles Biologiques", Aulnay, France. Study 25 January - 3 February 1984. Report 12 June 1992.
  12. A. Seeberg. Test substance: 3389 PAN: *Unscheduled DNA Synthesis in Human Cells. Cell Line: Hela S3. LSR RTC, Report No. 088104-M-10085, 1985*
  13. H. Haddouk. Bone Marrow Micronucleus Test by Oral Route in Mice. CIT Study No. 21426 MAS, 2001
  14. G. Erexson. *In Vivo Mouse Micronucleus Assay in 2-Nitro-5-glyceryl methylaniline (B060). Covance Study No. 6182-115, 2005*
  15. B. Molinier. Reverse Mutation Assay on Bacteria *Salmonella typhimurium* and *Escherichia coli*. CIT Study No. 11570 MMJ (CIES1 94023), 1994
  16. M. Lloyd. 2-nitro-5-glyceryl methylaniline (B060): Mutation at the Thymidine Kinase (*tk*) Locus of Mouse Lymphoma L578Y Cells (MLA) using the Microtitre® Fluctuation Technique. Covance Study No. 413/92, 2005
  17. M. Lloyd. 2-Nitro-5-glyceryl methylaniline (B060): Mutation at the *hprt* locus of L5178Y Mouse Lymphoma Cells using the Microtitre® Fluctuation Technique. Covance Study No.413/127, 2005
  18. V. Thybaud, M. Aardema, J. Clements, K. Dearfield, S. Gallowa , M. Hayashif, D. Jacobson-Kram, D. Kirkland, J.T. MacGregor, D. Marzin, W. Ohyama, M. Schuler, H. Suzuki, E. Zeiger Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to *in vitro* testing, *Mutation Research*, 2007, 627 : 41–58
  19. M. Reichenbach. *In vivo* *Unscheduled DNA Synthesis* in rat hepatocytes with 2-nitro-5-glyceryl methylaniline. Harlan Study No 1252300, 2009
  20. Akomeah FK, Martin GP, Brown MB. Variability in Human Skin Permeability *in vitro*: Comparing Penetrants with Different Physicochemical Properties. *J. Pharm. Sci.*, 2007, 96 (4): 824-834.

### Submission III, 2005

References in *italics* [15-25] are not submitted as full reports in the present dossier. They consist of reports on preliminary toxicity studies [15-17] and reports for studies considered to be inadequate [18-25]. These can be provided upon request.

1. J. Clouzeau. Imexine FT: Acute Oral Toxicity in Rats. CIT Study No. 8797 TAR (CIES1 92014), 1992
2. J. Clouzeau. Imexine FT at 1%: Acute Dermal Irritation in Rabbits. CIT Study No. 8798 TAL (CIES1 92016), 1992
3. J. Clouzeau. Imexine FT at 1%: Acute Eye Irritation in Rabbits. CIT Study No. 8799 TAL (CIES1 92015), 1992
4. G. Sire. 2-Nitro-5-glyceryl methylaniline (B060): Evaluation of Skin Sensitization Potential in Mice using the Local Lymph Node Assay (LLNA). CIT Study No. 27941 TSS, 2005
5. C. Fabreguettes. Imexine FT: 13-Week Toxicity Study by Oral Route in Rats. CIT Study No. 11389 TCR (CIES1 94022), 1995
6. B. Molinier. Imexine FT: Reverse Mutation Assay on Bacteria *Salmonella typhimurium* and *Escherichia coli*. CIT Study No. 11570 MMJ (CIES1 94023), 1994

7. M. Lloyd. 2-nitro-5-glyceryl methylaniline (B060): Mutation at the Thymidine Kinase (tk) Locus of Mouse Lymphoma L5178Y Cells (MLA) using the Microtitre® Fluctuation Technique. Covance Study No. 413/92, 2005
8. M. Lloyd. 2-Nitro-5-glyceryl methylaniline (B060): Mutation at the hprt locus of L5178Y Mouse Lymphoma Cells using the Microtitre® Fluctuation Technique. Covance Study No.413/127, 2005
9. A. Seeberg. Test substance: 3389 PAN: Unscheduled DNA Synthesis in Human Cells. Cell Line: Hela S3. LSR RTC, Report No. 088104-M-10085, 1985
10. H. Haddouk. Imexine FT: Bone Marrow Micronucleus Test by Oral Route in Mice. CIT Study No. 21426 MAS, 2001
11. G. Erexson. In Vivo Mouse Micronucleus Assay in 2-Nitro-5-glyceryl methylaniline (B060). Covance Study No. 6182-115, 2005
12. M.-H. Savary. Imexine FT: Assessment of Possible Embryotoxic or Teratogenic Effects by Oral Route in Rats. CIT Study No. 6905 RSR (CIAC090076), 1991
13. R. Ligt. In Vitro Percutaneous Absorption of [14C]-2-nitro-5-glyceryl-methylaniline through human skin membranes using flow-through diffusion cells. TNO Study No. 6218, 2005
14. D. Mathieu. 2-Nitro-5-glyceryl methylaniline (B060): Validation of the Analytical Method and Determination of Homogeneity and Stability of Dosage Forms. CIT Study No. 27940 AHS, 2005
15. C. Fabreguettes. *Preliminary Toxicity Study for 14 Days by Oral Administration (Gavage) to Rats. CIT Study No. 5661 TSR, 1990*
16. C. Fabreguettes. *Toxicity Study for 28 Days by Oral Administration (Gavage) to Rats. CIT Study No. 5957 TSR, 1990*
17. F. Bourcier. *Assessment of Possible Embryotoxic or Teratogenic Effects by Oral Route in Rats. CIT Study No. 6033 RSR (CIAC090015), 1991*
18. J. Clouzeau. *Acute Dermal Irritation in Rabbits. CIT Study No. 11778 TAL (CIAUL 94046), 1994*
19. J. Clouzeau. *Acute Eye Irritation in Rabbits. CIT Study No. 11779 TAL (CIAUL 94045), 1994*
20. S. de Jouffrey. *Skin Sensitization Test in Guinea Pigs. (Maximization method of Magnusson, B. and Kligman, A.M.). CIT Study No. 11780 TSG (CIAUL 94047), 1995*
21. J-F. Guillot. *Test pour l'évaluation du pouvoir sensibilisant, par applications topiques, chez le cobaye. IFREB study No. 112325, 1981*
22. C. Tortil. *Mutagenic evaluation of the compound 1-methylamino-2-nitro-5-(2,3-dihydroxypropyloxy)-benzene (Ref. op26) in Ames salmonella typhimurium plate test. L'Oréal study No. MMS 1 - 26/2/1986, 1992*
23. A.T. Natarajan. *Evaluation of compound 3-methylamono-4-nitrophenyl-dihydroxy propylether in the chromosome aberration test with Chinese hamster ovary cells (in vitro). Department of radiation, genetics and chemical mutagenesis, 1987*
24. J. Whitwell. *2-nitro-5-glyceryl methylaniline: induction of chromosome aberrations in cultured Chinese hamster ovary (CHO) cells. Covance Study No. 413/37, 2000*
25. M. Cottin. *Pénétration du colorant Imexine FT à travers l'épiderme humain monté sur cellules de diffusion type Franz. L'Oréal study No. 89/10/502 and 89/10/503, 199*

### Submission II, 2001

11. 2-Nitro-5-glyceryl methylaniline : induction of chromosome aberrations in cultured Chinese hamster Ovary (CHO) cells. Covance Laboratories Ltd, North Yorkshire HG 1 1PY, England. Report n° 413/37 - DG 1682, August 2000
12. IMEXINE FT. Bone marrow Micronucleus test by oral route in mice. CIT F 27005 Evreux. Report n° 21426 MAS, 21 May 2001

### Submission I, 1993

1. Acute Oral Toxicity in Rats. IMEXINE FT (batch Op 8). Centre International de Toxicologie, (CIT), Evreux, France. Study No 8797 TAR, 25 May 1992.
2. Acute Eye Irritation in Rabbits. Test Substance IMEXINE FT at 1% (batch Op 8). Centre International de Toxicologies (CIT), Evreux, France. Study No 8799 TAL, 21 May 1992. Amendment No 1 to the final report, 20 July 1992.
3. Acute Dermal Irritation in Rabbits. IMEXINE FT at 1% (batch Op 8). Centre International de Toxicologie, (CIT), Evreux, France. Study No 8798 TAL, 25 May 1992. Amendment No 1 to the final report, 20 July 1992.
4. IFD 174.81 Colorant (prélèvement DG2). "Evaluation of the Sensitising Potential of a Test Substance by Topical Applications in the Guinea Pig". Institut Français de Recherches et Essais Biologiques (IFREB), Saint Germain-sur-l'Arbresle - France. Report IFREB R112325 - 15 December 1981
5. Toxicity Study for 28 Days by Oral Administration (gavage) to Rats. IMEXINE FT". Centre International de Toxicologie, - Evreux, France Report No 5957 TSR - 3.10.1990.
6. Assessment of Possible Embryotoxic or Teratogenic Effects by Oral Route in Rats. Test Article IMEXINE FT" Centre International de Toxicologie (CIT) - Miserey-27005 Evreux, France Study No 6905 RSR, 26 June 1991.
7. Mutagenic Evaluation of the Compound l-Methylamino-2-nitro-5-(2,3-dihydroxypropyloxy)-benzene (Ref: op 26) in Ames Salmonella Typhimurium Plate Test". L'OREAL, Department of Chemical Protection and Photobiological Research in Vitro, Advanced Research Center - Aulnay-sous-Bois - France. Report of 2.6.86, rev. 6.2.92.
8. Evaluation of Compound 3-Methylamino-4-Nitrophenyl-Dihydroxy Propylether in the Chromosome Aberration Test with Chinese Hamster Ovary Cells (*in vitro*). University of Leiden - NL. Department of Radiation Genetics and Chemical Mutagenesis. 27 July 1987.
9. "Test du Micronoyau sur Moelle Osseuse de Souris Traitée *in vivo* par Voie Intrapéritonéale. Produit testé B 60, l-Méthylamino-2-Nitro-5(2,3-Dihydroxypropyloxy)-Benzène". Département des "Contrôles Biologiques", L'OREAL, Aulnay, France. Study 25 January - 3 February 1984. Report 12 June 1992.
10. Pénétration du Colorant IMEXINE FT à travers l'épiderme Humain Monté sur Cellules de Diffusion type Franz. Chimie Analytique - Contrôles Biologiques et Méthodes Alternatives, Aulnay-sous-Bois France. 25 January, 1990